The Association for Research in Vision and Ophthalmology (ARVO) 2016 conference takes place next week, May 1-5, 2016, at the Washington State Convention Center in Seattle, Wash.
Over the past week, a number of companies have announced they plan to present the latest and greatest in research and product information at ARVO 2016. Here's a look at some of the what you can expect to see at this year's show.
- Dr. Ryo Kubota, MD, PhD, and Chairman, President and CEO of Acucela will present an education course titled “Intellectual Property and Patenting in Vision and Ophthalmic Research” on April 30th.
- Allergan will conduct 18 presentations at ARVO featuring data that span retina, ocular surface and glaucoma subspecialties.
- Graybug Vision, Inc. will present data from a murine study of GB-102 in a poster on May 2nd, and then will present data from an in vivo toxicology/PK study of GB-102 in a poster on May 4th.
- Inotek Pharmaceuticals Corporation will offer three post presentations — two on May 4th and one on May 5th.
- Integral BioSystems LLC will be both an exhibitor and presenter of two posters.
- Omeros Corporation will present new research related to the clinical utility of Omidria (phenylephrine and ketorolac injection) 1%/0.3% and the importance of preempting intraoperative miosis and inflammation during cataract surgery on May 1st.
- Clinical researchers participating in ProgSTAR, the largest natural history study ever launched for Stargardt disease, will deliver six posters and four paper presentations on their interim findings.
- RXi Pharmaceuticals Corporation will present new data from ongoing research utilizing the Company's proprietary RNAi platform in the area of therapeutic topical delivery to the eye on May 1st.
- ThromboGenics NV will present a number of scientific posters and presentations at ARVO, with preclinical research findings, real-world clinical data, and further characterization of results from different studies, including OASIS, ORBIT, and OVIID-I conducted in the US and Europe.
Photo courtesy ARVO.